Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
Clicks: 166
ID: 118491
2012
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
166 views
19 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #344 of 1,084 articles by views in clinical infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract. Recurrence of Clostridium difficile infection (CDI) occurs in approximately 25% of successfully treated patients. Two phase 3 randomized, double-blin
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (18 words).
Try re-searching for a better abstract.
| Reference Key |
a.2012clinicaltreatment
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Cornely, Oliver A.;Miller, Mark A.;Louie, Thomas J.;Crook, Derrick W.;Gorbach, Sherwood L.; |
| Journal | clinical infectious diseases |
| Year | 2012 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.